Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...

Overview of Protein Metabolism

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High-resolution structure of monomorphic Aβ<sub>1-40</sub> fibrils.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

The chaperone DNAJB6b halts amyloid formation through association with transient Aβ oligomers.

Physical chemistry chemical physics : PCCP·2026

Same author

The temperature dependence of amyloid <i>β</i> solubility reveals the hydrophobic effect as the main driving force for fibril formation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Rapid elongation drives the exceptionally fast aggregation of the most common localized human amyloid medin.

Communications chemistry·2026

Same author

Transient Interactions of α-Synuclein N- and C-Termini.

ACS chemical neuroscience·2026

Same author

Correction to "Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification Assay".

Journal of the American Chemical Society·2026

Search research articles

Related Experiment Video

Updated: May 23, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Reduced protein solubility - cause or consequence in amyloid disease?

Max Lindberg¹, Jing Hu², Emma Sparr²

¹Biochemistry and Structural Biology, Lund University, Lund, Sweden.

|March 12, 2025

Summary

Investigating Alzheimer's disease, this study questions if reduced amyloid beta 42 (Aβ42) solubility causes or results from protein deposition. It explores physicochemical explanations for lower Aβ42 levels in cerebrospinal fluid, impacting disease understanding.

Keywords:

Alzheimer associated amyloids amyloid complexes biomolecular systems chaperones physical chemistry protein biophysics

More Related Videos

Rapid Generation of Amyloid from Native Proteins In vitro

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Published on: April 28, 2022

Related Experiment Videos

Last Updated: May 23, 2025

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Rapid Generation of Amyloid from Native Proteins In vitro

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Published on: April 28, 2022

Area of Science:

Neuroscience
Biochemistry
Physical Chemistry

Background:

Amyloid diseases, such as Alzheimer's disease, are characterized by protein deposition.
A reduction in cerebrospinal fluid (CSF) concentration of amyloid beta peptide, specifically Aβ42, is often observed in Alzheimer's disease patients.

Purpose of the Study:

To investigate whether the observed lower solubility of specific proteins, particularly Aβ42, is a cause or a consequence of protein deposition in amyloid diseases.
To explore potential physicochemical explanations for reduced Aβ42 concentrations in CSF.

Main Methods:

Review of experimental evidence regarding Aβ42 concentrations in CSF.
Analysis of physicochemical principles governing protein solubility and aggregation.
Theoretical exploration of metastable states in protein solutions.

Main Results:

Several physicochemical explanations for reduced Aβ42 levels are proposed, including true reduced solubility and reduced apparent solubility.
The concept of a long-lived metastable state for Aβ42 is introduced, where concentrations exceed solubility limits without immediate precipitation.
The study evaluates whether these scenarios represent a cause or consequence of Aβ42 deposition.

Conclusions:

The observed reduction in CSF Aβ42 levels in Alzheimer's disease may stem from various physicochemical phenomena, not solely a direct cause-effect relationship with deposition.
Understanding these states is crucial for differentiating between cause and consequence in Aβ42 pathology.
Further research is needed to elucidate the precise mechanisms driving Aβ42 behavior in Alzheimer's disease.